Literature DB >> 8381161

Comparative study of p53 gene and protein alterations in human astrocytic tumors.

D N Louis1, A von Deimling, R Y Chung, M P Rubio, J M Whaley, R H Eibl, H Ohgaki, O D Wiestler, A D Thor, B R Seizinger.   

Abstract

The p53 gene is a tumor suppressor gene involved in many common malignancies, including astrocytomas. Genetic analysis of the p53 gene and immunohistochemistry of the p53 protein have each been used to screen astrocytomas. To compare these methods, we performed immunohistochemistry with the monoclonal antibody PAb 1801 and single-strand conformational polymorphism (SSCP) with sequence analysis on 34 astrocytic tumors (WHO grades II, III and IV). Seven cases had detectable p53 protein and gene mutations, while twelve cases had neither detectable protein nor gene mutations. Four tumors had frameshift mutations in the p53 gene that were not revealed by immunohistochemistry. One tumor had a genetic polymorphism and no detectable p53 protein. Ten tumors had p53 protein accumulation but no mutations by SSCP; these cases may represent p53 mutations outside of the conserved exons or elevated levels of wild-type p53 protein. Thus, some p53 mutations are missed with PAb 1801 immunohistochemistry alone. p53 immunohistochemistry, however, may reveal p53 accumulation independent of mutations in the conserved portions of the gene. Finally, we suggest that glioblastomas with p53 mutations in the conserved region of the gene may be a subset that are more common in women and in younger patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381161     DOI: 10.1097/00005072-199301000-00005

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  52 in total

Review 1.  Glioma classification: a molecular reappraisal.

Authors:  D N Louis; E C Holland; J G Cairncross
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

Review 2.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

3.  Proliferative index facilitates distinction between benign biliary lesions and intrahepatic cholangiocarcinoma.

Authors:  Christos G Tsokos; Gregor Krings; Funda Yilmaz; Linda D Ferrell; Ryan M Gill
Journal:  Hum Pathol       Date:  2016-07-07       Impact factor: 3.466

4.  p53 protein in pediatric malignant astrocytomas: a study of 21 patients.

Authors:  M B Bhattacharjee; J M Bruner
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

Review 5.  Developmental origins and oncogenic pathways in malignant brain tumors.

Authors:  Q Richard Lu; Lily Qian; Xianyao Zhou
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2019-04-03       Impact factor: 5.814

6.  A better surgical resectability of WHO grade II gliomas is independent of favorable molecular markers.

Authors:  Dominik Cordier; Catherine Gozé; Sabine Schädelin; Valérie Rigau; Luigi Mariani; Hugues Duffau
Journal:  J Neurooncol       Date:  2014-09-28       Impact factor: 4.130

7.  Glioblastoma multiforme in four siblings: a cytogenetic and molecular genetic study.

Authors:  C M Dirven; J Tuerlings; W M Molenaar; K G Go; D N Louis
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

8.  Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.

Authors:  Xiang Wang; Jin-xiu Chen; Yan-hui Liu; Chao You; Qing Mao
Journal:  Neurol Sci       Date:  2012-12-08       Impact factor: 3.307

9.  Alterations in tumour suppressor gene p53 in human gliomas from Indian patients.

Authors:  Poornima Phatak; S Kalai Selvi; T Divya; A S Hegde; Sridevi Hegde; Kumaravel Somasundaram
Journal:  J Biosci       Date:  2002-12       Impact factor: 1.826

10.  Apoptosis and p53 expression in human gliomas.

Authors:  L Sipos; Z Szegedi; I Fedorcsák; D Afra; B Szende
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.